TNFRSF17 and Miyoshi myopathy: B cell maturation antigen (BCMA), type III transmembrane receptor which belongs to tumor necrosis factor superfamily member 17, known as TNFRSF17/CD269, is one of the most attractive antigens in the development of immunotherapies of MM, because it is exclusively expressed in most plasma cells, compared with CD38 and SLAMF7.